MIG AG

MIG Verwaltungs AG is a Munich-based venture capital firm that focuses on investing in small and medium-sized enterprises across various industries, with a particular emphasis on life sciences and technology. Established in 2004, the firm targets investments in sectors such as artificial intelligence, machine learning, quantum technology, digitalization, medical technology, digital health, and biopharmaceuticals. MIG AG primarily invests in companies located in Germany, Austria, and Switzerland, with a minimum investment threshold of €0.1 million. The firm typically holds its investments for a duration of four to eight years before seeking an exit. Through its strategic investments, MIG AG aims to foster innovation and contribute to advancements in technology and healthcare.

Klaus Feix Ph.D

Venture Partner

Andreas Kastenbauer

Venture Partner

Jürgen Kosch

Co-Founder and Managing Partner

Axel Thierauf

Venture Partner

Fei Tian Ph.D

Principal

89 past transactions

CoreMedic

Series B in 2025
CoreMedic develops innovative devices for treating heart valve diseases. Its flagship product is ChordArt, a minimally invasive mitral valve repair system that addresses regurgitation by replacing or reinforcing chordae tendineae via a trans-femoral approach at the beating heart.

Liva Healthcare

Venture Round in 2025
Liva Healthcare is a digital health coaching platform focused on scalable lifestyle and disease management, particularly for chronic conditions such as Type 2 diabetes, obesity, and heart disease. The company provides an intuitive app that fosters personalized health coaching, creating strong connections between coaches, general practitioners, and patients. Its platform is designed to engage patients over nine to 18 months, promoting sustainable behavior change and habit formation. Liva Healthcare's services are utilized by various organizations, including public healthcare systems and private insurers. The app is multilingual and effective across diverse socio-economic groups, allowing one coach to manage up to 500 patients simultaneously. Implementation typically occurs within weeks, and the platform is offered as both a white-label Software as a Service solution and a turn-key option, tailored to client needs. Liva Healthcare operates from offices in Copenhagen, Denmark, and London, UK.

Inbolt

Series A in 2024
Inbolt is a company focused on enhancing industrial operations through advanced vision systems for robots. It has developed a vision-based artificial intelligence that enables real-time decision-making in various environments, allowing for smarter automation of complex tasks. The company's technology includes a tool positioning system that provides real-time quality control for manual operations such as torquing, drilling, and riveting. By implementing these innovations, Inbolt aims to reduce errors in operations and improve overall quality control, thereby streamlining industrial processes and increasing efficiency.

SciRhom

Series A in 2024
SciRhom GmbH is a biotechnology company focused on the preclinical and early clinical development of innovative biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Established in 2016 through a collaboration between experienced academic and industry scientists, the company leverages extensive research and a robust network of experts in antibody development. SciRhom specializes in creating therapeutic antibodies targeting iRhom2, a significant modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. This focus allows the company to develop improved treatment options that enhance the protection of skin and intestinal barriers, ultimately benefiting patients suffering from serious autoimmune conditions.

Innatera

Series A in 2024
Innatera develops ultra-low-power neuromorphic processors for sensors. Founded in 2018 as a spin-off from Delft University of Technology, the company designs neuromorphic chips that mimic brain mechanisms for processing sensory data. The processors use continuous-time analog-mixed signal computing to replicate spiking neurons and synapses, enabling sensor data to be processed faster and with substantially less energy than conventional processors.

HawkCell

Series A in 2024
HawkCell specializes in advanced magnetic resonance imaging (MRI) solutions for veterinary clinics and preclinical research labs. Utilizing non-ionizing, three-dimensional MRI technology adapted for diverse animal morphologies, the company offers sustainable systems enhanced by artificial intelligence algorithms to provide precise and insightful animal healthcare services.

Look Up Space

Seed Round in 2023
Look Up Space specializes in space safety and security. It operates a global radar network for detecting and tracking orbital threats, offering real-time analysis and secure data processing capabilities to ensure sustainable space operations.

AMSilk

Series C in 2023
AMSilk GmbH is a Munich-based company that specializes in the production of spider silk proteins and other biomaterials for a variety of industrial applications. Founded in 2008, AMSilk manufactures high-quality silk biopolymers that serve diverse sectors, including pharmaceuticals, cosmetics, and technical textiles. Its product offerings include BioShield-S1, a non-immunogenic spider silk film for protective coatings, as well as biosteel spider silk fibers. The company also develops a range of wound care products and surgical applications, such as the SanaSilk durable skin barrier. Additionally, AMSilk provides spider silk protein beads and coatings for medical technology, alongside nonwovens for filters, wound dressings, and specialty textiles. Utilizing a patented biotechnological process, AMSilk's materials are fully biodegradable under aerobic and marine conditions, promoting sustainability in various applications. The company collaborates with partners like Gruschwitz Textilwerke AG to enhance its product offerings.

talpasolutions

Series B in 2023
talpasolutions a predictive SaaS analytics provider for the mining industry that helps companies optimize machine performance, reduce breakdowns, and improve safety by making data more understandable. talpasolutions makes it possible for operators and machine manufacturers in heavy industry to use machine data that would have otherwise been lost. talpasolutions concentrates on building visualization and analysis applications for the industrial internet. In the first step, large amounts of data from the machines are recorded. Comprehendable visualizations allow for different stakeholders to understand relationships based on sensor data and contextual data and to react to critical information, which would otherwise have been buried in the data transfer. In the second step the newest predictive models are applied to eliminate events such as errors and the breakdown of machines critical to the process. This increases not only the availability but also the workload of the machines. talpasolutions has built a network out of industry partners to develop solutions that stretch across various sectors and unify industry experience, data science, and workflow connectivity. Using predictive instructions our platform recognizes problems before they occur and supports users with workflow-based processes. Our applications make it possible to collect performance data from machines in order to recommend optimal fleet combinations for respective scenarios to customers. This leads to more operating hours, higher efficiency, and an improved lifetime value of the machines.

Mbiomics

Series A in 2023
Mbiomics is a biotechnology company focused on transforming microbiome research, diagnostics, and therapeutics. The firm operates a high-throughput, low-cost platform designed for dynamic and real-time analysis and quantification of the human gut microbiome. This technology enables precise diagnostics and targeted therapies, aiming to enhance patients' lives through innovative approaches to health management.

KEWAZO

Series A in 2023
KEWAZO develops autonomous robotics systems for construction sites. Its primary product is LIFTBOT, a robotic material hoist that safely transports scaffolding parts during assembly, reducing labor costs by up to 44%, addressing labor shortages, and enhancing safety. Additionally, Kewazo collects operational data from its robots on-site, providing customers with a data analytics platform for proactive project management.

Inbolt

Seed Round in 2022
Inbolt is a company focused on enhancing industrial operations through advanced vision systems for robots. It has developed a vision-based artificial intelligence that enables real-time decision-making in various environments, allowing for smarter automation of complex tasks. The company's technology includes a tool positioning system that provides real-time quality control for manual operations such as torquing, drilling, and riveting. By implementing these innovations, Inbolt aims to reduce errors in operations and improve overall quality control, thereby streamlining industrial processes and increasing efficiency.

NavVis

Venture Round in 2021
NavVis develops indoor spatial intelligence solutions, enabling enterprises to capture and share built environments as photorealistic digital twins. Its SLAM-based mobile mapping systems generate high-quality data with survey-grade accuracy, facilitating better operational decisions and improved productivity.

GoBolt

Series B in 2021
GoBolt, formerly known as Second Closet Incorporated, provides valet self-storage services that enable customers to store their belongings conveniently and securely. Founded in 2017 and based in Toronto, Canada, the company offers a comprehensive solution where customers can schedule pickups and returns of their items. GoBolt delivers boxes for customers to use for storage, then collects these items to be stored in a climate-controlled warehouse. The service is designed to be user-friendly, allowing clients to pay only for the space they utilize, making it an affordable option for those in need of storage solutions.

Efficient Energy

Series A in 2021
Efficient Energy GmbH, based in Feldkirchen near Munich, Germany, specializes in the development, manufacturing, and distribution of environmentally friendly refrigeration systems for both industrial and home applications. Established in 2006, the company is recognized for its innovative eChiller, which utilizes pure water as a refrigerant, effectively avoiding the use of harmful fluorinated gases. This technology addresses regulatory challenges in refrigeration while providing efficient cooling solutions for data centers, server rooms, and various industrial processes. The eChiller models offer cooling capacities ranging from 35 kW to 120 kW and are designed to deliver cost efficiency and a low carbon footprint. Efficient Energy also provides a range of services, including consulting, planning, installation, and maintenance, ensuring optimal energy efficiency for its clients. The company's pioneering work has garnered multiple awards, highlighting its commitment to sustainable practices in refrigeration technology.

iOmx Therapeutics

Series B in 2021
iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The company focuses on creating first-in-class cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. Utilizing a proprietary siRNA-based screening technology, iOmx systematically analyzes human tumor cells to identify innovative therapeutic targets and understand their mechanisms of action. The company's approach is rooted in the principles of cancer immune-checkpoint therapy, which aims to overcome tumors' inherent resistance to immune attacks. This resistance is often mediated by cell surface molecules that inhibit T cell activation. By neutralizing these negative interactions, iOmx Therapeutics seeks to reactivate the host immune response, ultimately enhancing the effectiveness of cancer treatments.

KEWAZO

Series A in 2021
KEWAZO develops autonomous robotics systems for construction sites. Its primary product is LIFTBOT, a robotic material hoist that safely transports scaffolding parts during assembly, reducing labor costs by up to 44%, addressing labor shortages, and enhancing safety. Additionally, Kewazo collects operational data from its robots on-site, providing customers with a data analytics platform for proactive project management.

AMSilk

Series C in 2021
AMSilk GmbH is a Munich-based company that specializes in the production of spider silk proteins and other biomaterials for a variety of industrial applications. Founded in 2008, AMSilk manufactures high-quality silk biopolymers that serve diverse sectors, including pharmaceuticals, cosmetics, and technical textiles. Its product offerings include BioShield-S1, a non-immunogenic spider silk film for protective coatings, as well as biosteel spider silk fibers. The company also develops a range of wound care products and surgical applications, such as the SanaSilk durable skin barrier. Additionally, AMSilk provides spider silk protein beads and coatings for medical technology, alongside nonwovens for filters, wound dressings, and specialty textiles. Utilizing a patented biotechnological process, AMSilk's materials are fully biodegradable under aerobic and marine conditions, promoting sustainability in various applications. The company collaborates with partners like Gruschwitz Textilwerke AG to enhance its product offerings.

GoBolt

Venture Round in 2021
GoBolt, formerly known as Second Closet Incorporated, provides valet self-storage services that enable customers to store their belongings conveniently and securely. Founded in 2017 and based in Toronto, Canada, the company offers a comprehensive solution where customers can schedule pickups and returns of their items. GoBolt delivers boxes for customers to use for storage, then collects these items to be stored in a climate-controlled warehouse. The service is designed to be user-friendly, allowing clients to pay only for the space they utilize, making it an affordable option for those in need of storage solutions.

Liva Healthcare

Series B in 2021
Liva Healthcare is a digital health coaching platform focused on scalable lifestyle and disease management, particularly for chronic conditions such as Type 2 diabetes, obesity, and heart disease. The company provides an intuitive app that fosters personalized health coaching, creating strong connections between coaches, general practitioners, and patients. Its platform is designed to engage patients over nine to 18 months, promoting sustainable behavior change and habit formation. Liva Healthcare's services are utilized by various organizations, including public healthcare systems and private insurers. The app is multilingual and effective across diverse socio-economic groups, allowing one coach to manage up to 500 patients simultaneously. Implementation typically occurs within weeks, and the platform is offered as both a white-label Software as a Service solution and a turn-key option, tailored to client needs. Liva Healthcare operates from offices in Copenhagen, Denmark, and London, UK.

German Bionic

Series A in 2020
German Bionic is a manufacturer of advanced exoskeletons designed to enhance efficiency and productivity in industrial processes. The company’s flagship product, the German Bionic Cray X, is recognized as the world's first connected exoskeleton. This innovative device integrates with Smart Factory systems, utilizing self-learning technology to support lifting movements and promote correct posture, thereby serving as an intelligent intermediary between human operators and machines. By delivering actionable data, the Cray X aims to protect worker health, reduce the risk of accidents, and improve overall work processes. German Bionic has received several prestigious awards, including the German Entrepreneur Award and the Automatica Award, highlighting its commitment to safety and innovation in the workplace.

Innatera

Seed Round in 2020
Innatera develops ultra-low-power neuromorphic processors for sensors. Founded in 2018 as a spin-off from Delft University of Technology, the company designs neuromorphic chips that mimic brain mechanisms for processing sensory data. The processors use continuous-time analog-mixed signal computing to replicate spiking neurons and synapses, enabling sensor data to be processed faster and with substantially less energy than conventional processors.

Efficient Energy

Venture Round in 2020
Efficient Energy GmbH, based in Feldkirchen near Munich, Germany, specializes in the development, manufacturing, and distribution of environmentally friendly refrigeration systems for both industrial and home applications. Established in 2006, the company is recognized for its innovative eChiller, which utilizes pure water as a refrigerant, effectively avoiding the use of harmful fluorinated gases. This technology addresses regulatory challenges in refrigeration while providing efficient cooling solutions for data centers, server rooms, and various industrial processes. The eChiller models offer cooling capacities ranging from 35 kW to 120 kW and are designed to deliver cost efficiency and a low carbon footprint. Efficient Energy also provides a range of services, including consulting, planning, installation, and maintenance, ensuring optimal energy efficiency for its clients. The company's pioneering work has garnered multiple awards, highlighting its commitment to sustainable practices in refrigeration technology.

KEWAZO

Seed Round in 2020
KEWAZO develops autonomous robotics systems for construction sites. Its primary product is LIFTBOT, a robotic material hoist that safely transports scaffolding parts during assembly, reducing labor costs by up to 44%, addressing labor shortages, and enhancing safety. Additionally, Kewazo collects operational data from its robots on-site, providing customers with a data analytics platform for proactive project management.

Biocrates Life Sciences

Venture Round in 2019
Biocrates Life Sciences AG is a biotechnology company based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions. Founded in 2002, the company develops and markets mass-spectrometry based kits and services that facilitate the analysis of endogenous metabolites. These tools are essential for discovering and validating biomarkers associated with complex multifactorial diseases, including cancer and neurodegenerative disorders. Biocrates provides a comprehensive metabolomics platform that integrates automated sample preparation workflows with advanced mass-spectrometric techniques, enabling rapid and reliable identification of hundreds of metabolites. Their products and services cater to a wide range of research areas, such as cardiovascular health, diabetes, endocrinology, pharmacology, and more. Biocrates Life Sciences distributes its solutions through authorized partners across various regions, including the Middle East, Europe, and parts of Asia.

IQM Quantum Computers

Seed Round in 2019
IQM Quantum Computers, founded in 2018 and headquartered in Espoo, Finland, specializes in developing and manufacturing hardware systems for quantum computing. The company focuses on scalable hardware solutions utilizing superconducting technology to build quantum processors for universal quantum computers. By concentrating on practical applications, IQM aims to enhance quantum computing capabilities and address challenges faced by various industries and society. As a spin-out from Aalto University and the VTT Technical Research Centre of Finland, IQM has achieved significant advancements in areas such as thermal management, which are crucial for improving computational speed and information accuracy. The company's innovations position it as a leader in the global pursuit of large-scale quantum computing solutions. IQM also offers access to its hardware for research laboratories and supercomputing centers, helping businesses reduce error rates that currently limit computing performance.

CYNORA

Series C in 2019
CYNORA GmbH is a Bruchsal, Germany-based company specializing in the development and manufacturing of organic electronics, particularly for organic light-emitting diode (OLED) displays. Founded in 2008, CYNORA focuses on creating advanced materials that utilize Thermally Activated Delayed Fluorescence (TADF) technology to produce efficient blue and green emitters. These emitters are designed to enhance the power efficiency and color contrast of OLED devices, addressing the growing demand for thinner, flexible screens with improved performance and lower energy consumption. By providing iridium-free, purely organic emitter systems tailored for modern vacuum processing, CYNORA aims to deliver significant value to OLED producers and meet the evolving expectations within the display market.

Liva Healthcare

Series A in 2019
Liva Healthcare is a digital health coaching platform focused on scalable lifestyle and disease management, particularly for chronic conditions such as Type 2 diabetes, obesity, and heart disease. The company provides an intuitive app that fosters personalized health coaching, creating strong connections between coaches, general practitioners, and patients. Its platform is designed to engage patients over nine to 18 months, promoting sustainable behavior change and habit formation. Liva Healthcare's services are utilized by various organizations, including public healthcare systems and private insurers. The app is multilingual and effective across diverse socio-economic groups, allowing one coach to manage up to 500 patients simultaneously. Implementation typically occurs within weeks, and the platform is offered as both a white-label Software as a Service solution and a turn-key option, tailored to client needs. Liva Healthcare operates from offices in Copenhagen, Denmark, and London, UK.

Efficient Energy

Venture Round in 2019
Efficient Energy GmbH, based in Feldkirchen near Munich, Germany, specializes in the development, manufacturing, and distribution of environmentally friendly refrigeration systems for both industrial and home applications. Established in 2006, the company is recognized for its innovative eChiller, which utilizes pure water as a refrigerant, effectively avoiding the use of harmful fluorinated gases. This technology addresses regulatory challenges in refrigeration while providing efficient cooling solutions for data centers, server rooms, and various industrial processes. The eChiller models offer cooling capacities ranging from 35 kW to 120 kW and are designed to deliver cost efficiency and a low carbon footprint. Efficient Energy also provides a range of services, including consulting, planning, installation, and maintenance, ensuring optimal energy efficiency for its clients. The company's pioneering work has garnered multiple awards, highlighting its commitment to sustainable practices in refrigeration technology.

KONUX

Series B in 2019
KONUX GmbH is a German company based in Munich, founded in 2014, that specializes in developing Industrial Internet of Things (IIoT) solutions for railway and industrial applications. The company integrates smart sensor systems with artificial intelligence-driven analytics to provide real-time monitoring of asset and infrastructure conditions, enabling predictive maintenance and enhancing operational efficiency. KONUX's offerings include switch monitoring, asset monitoring, rolling stock monitoring, anomaly detection, and customized hardware solutions. By leveraging machine learning and IoT technologies, KONUX aims to transform railway operations, making them more sustainable, reliable, and cost-effective. The company has expanded its footprint across Europe and Asia and has gained recognition as one of the most innovative startups globally, underscoring its commitment to modernizing transportation systems.

NavVis

Series C in 2018
NavVis develops indoor spatial intelligence solutions, enabling enterprises to capture and share built environments as photorealistic digital twins. Its SLAM-based mobile mapping systems generate high-quality data with survey-grade accuracy, facilitating better operational decisions and improved productivity.

GWA Hygiene

Venture Round in 2018
GWA Hygiene GmbH is a German company based in Stralsund, established in 2015, that specializes in the development of hygiene monitoring solutions for healthcare settings. The company manufactures sensors designed to monitor hand hygiene standards among hospital personnel and is expanding its offerings to include surface disinfection monitoring. GWA Hygiene's technology integrates with disinfectant and soap dispensers, equipping them with sensors to capture data on disinfection practices. This data can be displayed on monitors and is accessible via a software application that analyzes disinfection rates across different wards and professional groups. Users have the option to store data on their own servers or utilize GWA Hygiene's secure cloud storage. Additionally, the company's software toolbox aids in logistical tasks related to hygiene management, such as managing dispenser refills and device maintenance.

Efficient Energy

Venture Round in 2018
Efficient Energy GmbH, based in Feldkirchen near Munich, Germany, specializes in the development, manufacturing, and distribution of environmentally friendly refrigeration systems for both industrial and home applications. Established in 2006, the company is recognized for its innovative eChiller, which utilizes pure water as a refrigerant, effectively avoiding the use of harmful fluorinated gases. This technology addresses regulatory challenges in refrigeration while providing efficient cooling solutions for data centers, server rooms, and various industrial processes. The eChiller models offer cooling capacities ranging from 35 kW to 120 kW and are designed to deliver cost efficiency and a low carbon footprint. Efficient Energy also provides a range of services, including consulting, planning, installation, and maintenance, ensuring optimal energy efficiency for its clients. The company's pioneering work has garnered multiple awards, highlighting its commitment to sustainable practices in refrigeration technology.

advanceCOR

Venture Round in 2018
advanceCOR is a clinical drug development company focused on therapeutics and diagnostics for heart and vascular diseases. Its activities span research, development, and plans for commercialization to enable personalized treatment of cardiovascular conditions. Lead candidates include Revacept, a human Fc fusion protein that prevents local platelet activation at sites of vascular injury; COR-2, a recombinant protein that interferes with foam cell formation and the uptake of cholesterol; and COR-3, a recombinant protein that binds to atherosclerotic plaques and bi-specifically captures circulating progenitor cells to promote plaque healing. The company also develops antibodies and fusion proteins targeting platelet receptors and other components involved in arterial thrombosis and plaque progression, with an emphasis on addressing acute events such as myocardial infarction and stroke.

KEWAZO

Seed Round in 2018
KEWAZO develops autonomous robotics systems for construction sites. Its primary product is LIFTBOT, a robotic material hoist that safely transports scaffolding parts during assembly, reducing labor costs by up to 44%, addressing labor shortages, and enhancing safety. Additionally, Kewazo collects operational data from its robots on-site, providing customers with a data analytics platform for proactive project management.

KONUX

Series B in 2018
KONUX GmbH is a German company based in Munich, founded in 2014, that specializes in developing Industrial Internet of Things (IIoT) solutions for railway and industrial applications. The company integrates smart sensor systems with artificial intelligence-driven analytics to provide real-time monitoring of asset and infrastructure conditions, enabling predictive maintenance and enhancing operational efficiency. KONUX's offerings include switch monitoring, asset monitoring, rolling stock monitoring, anomaly detection, and customized hardware solutions. By leveraging machine learning and IoT technologies, KONUX aims to transform railway operations, making them more sustainable, reliable, and cost-effective. The company has expanded its footprint across Europe and Asia and has gained recognition as one of the most innovative startups globally, underscoring its commitment to modernizing transportation systems.

BioNTech

Series A in 2018
BioNTech is a Germany-based biotechnology company that specializes in developing innovative immunotherapies for cancer and other serious diseases, as well as vaccines for infectious diseases, including COVID-19. The company’s oncology pipeline includes a range of drug classes, such as mRNA-based drugs that encode antigens and neoantigens, cell therapies, bispecific antibodies, and antibody-drug conjugates. BioNTech has established partnerships with several major pharmaceutical companies, enhancing its research and development capabilities. Its COVID-19 vaccine, Comirnaty, represents its first commercialized product, demonstrating the company's commitment to addressing urgent health challenges through advanced therapeutic approaches.

Siltectra

Series B in 2017
SILTECTRA GmbH, founded in 2010 and based in Dresden, Germany, specializes in advanced laser-based wafering technology for semiconductor manufacturers. The company has developed innovative kerfless wafering and thinning solutions that enable the separation of wafers from semiconductor materials, such as silicon carbide, gallium nitride, and sapphire, without material loss. This technology is particularly beneficial for applications in solar inverters and various electronic devices, providing significant performance and cost advantages to the global semiconductor industry. SILTECTRA operates as a subsidiary of Infineon Technologies AG and aims to enhance manufacturing processes across multiple industries through its cutting-edge solutions.

Hemovent

Series A in 2017
Hemovent is a medical technology company based in Aachen, Germany, focused on developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Founded by Christof Lenz and Oliver Marseille, the company aims to create an innovative device that supports or replaces heart and lung functions during cardiac or respiratory failure. Hemovent's device is designed to provide respiratory support for patients with severely damaged lungs and serves as a temporary life support system, taking over heart function in cases of acute heart failure. This technology enables hospitals to stabilize patients and address underlying health issues effectively, while also allowing for increased patient mobility during treatment.

Efficient Energy

Venture Round in 2017
Efficient Energy GmbH, based in Feldkirchen near Munich, Germany, specializes in the development, manufacturing, and distribution of environmentally friendly refrigeration systems for both industrial and home applications. Established in 2006, the company is recognized for its innovative eChiller, which utilizes pure water as a refrigerant, effectively avoiding the use of harmful fluorinated gases. This technology addresses regulatory challenges in refrigeration while providing efficient cooling solutions for data centers, server rooms, and various industrial processes. The eChiller models offer cooling capacities ranging from 35 kW to 120 kW and are designed to deliver cost efficiency and a low carbon footprint. Efficient Energy also provides a range of services, including consulting, planning, installation, and maintenance, ensuring optimal energy efficiency for its clients. The company's pioneering work has garnered multiple awards, highlighting its commitment to sustainable practices in refrigeration technology.

AFFiRiS

Venture Round in 2017
AFFiRiS AG is a biotechnology company based in Vienna, Austria, specializing in the development and manufacture of peptide-based vaccines aimed at the therapeutic treatment of chronic diseases with significant unmet medical needs. Founded in 2003, the company focuses on creating tailored vaccines for a range of conditions, including Alzheimer’s disease, Parkinson’s disease, atherosclerosis, hypertension, diabetes, psoriasis, allergies, asthma, and Huntington’s disease, among others. Through its innovative approach, AFFiRiS seeks to address critical health challenges and improve patient outcomes in various therapeutic areas.

LXP Group

Series A in 2017
LXP Group develops LX-Process, an energy processing technology that treats 2G biomass to enable production of bio-based fuels and chemicals. The process converts biomass into the main components cellulose, hemicellulose, and lignin, and can be applied to convert leftover agricultural residues into bio-based chemicals and fuels. LX-Process can be scaled for large 2G ethanol manufacturing while also enabling economic retrofitting of smaller, decentralized biogas plants, and it addresses inhibitors formed during pre-treatment that hinder other methods. The company provides a pathway from agricultural waste to sustainable fuels and chemicals, supporting decarbonization goals. LXP Group is based in Marienwerder, Germany, and has been active since 2009.

Siltectra

Series B in 2017
SILTECTRA GmbH, founded in 2010 and based in Dresden, Germany, specializes in advanced laser-based wafering technology for semiconductor manufacturers. The company has developed innovative kerfless wafering and thinning solutions that enable the separation of wafers from semiconductor materials, such as silicon carbide, gallium nitride, and sapphire, without material loss. This technology is particularly beneficial for applications in solar inverters and various electronic devices, providing significant performance and cost advantages to the global semiconductor industry. SILTECTRA operates as a subsidiary of Infineon Technologies AG and aims to enhance manufacturing processes across multiple industries through its cutting-edge solutions.

KONUX

Series A in 2017
KONUX GmbH is a German company based in Munich, founded in 2014, that specializes in developing Industrial Internet of Things (IIoT) solutions for railway and industrial applications. The company integrates smart sensor systems with artificial intelligence-driven analytics to provide real-time monitoring of asset and infrastructure conditions, enabling predictive maintenance and enhancing operational efficiency. KONUX's offerings include switch monitoring, asset monitoring, rolling stock monitoring, anomaly detection, and customized hardware solutions. By leveraging machine learning and IoT technologies, KONUX aims to transform railway operations, making them more sustainable, reliable, and cost-effective. The company has expanded its footprint across Europe and Asia and has gained recognition as one of the most innovative startups globally, underscoring its commitment to modernizing transportation systems.

AFFiRiS

Venture Round in 2016
AFFiRiS AG is a biotechnology company based in Vienna, Austria, specializing in the development and manufacture of peptide-based vaccines aimed at the therapeutic treatment of chronic diseases with significant unmet medical needs. Founded in 2003, the company focuses on creating tailored vaccines for a range of conditions, including Alzheimer’s disease, Parkinson’s disease, atherosclerosis, hypertension, diabetes, psoriasis, allergies, asthma, and Huntington’s disease, among others. Through its innovative approach, AFFiRiS seeks to address critical health challenges and improve patient outcomes in various therapeutic areas.

Siltectra

Series B in 2016
SILTECTRA GmbH, founded in 2010 and based in Dresden, Germany, specializes in advanced laser-based wafering technology for semiconductor manufacturers. The company has developed innovative kerfless wafering and thinning solutions that enable the separation of wafers from semiconductor materials, such as silicon carbide, gallium nitride, and sapphire, without material loss. This technology is particularly beneficial for applications in solar inverters and various electronic devices, providing significant performance and cost advantages to the global semiconductor industry. SILTECTRA operates as a subsidiary of Infineon Technologies AG and aims to enhance manufacturing processes across multiple industries through its cutting-edge solutions.

KONUX

Series A in 2016
KONUX GmbH is a German company based in Munich, founded in 2014, that specializes in developing Industrial Internet of Things (IIoT) solutions for railway and industrial applications. The company integrates smart sensor systems with artificial intelligence-driven analytics to provide real-time monitoring of asset and infrastructure conditions, enabling predictive maintenance and enhancing operational efficiency. KONUX's offerings include switch monitoring, asset monitoring, rolling stock monitoring, anomaly detection, and customized hardware solutions. By leveraging machine learning and IoT technologies, KONUX aims to transform railway operations, making them more sustainable, reliable, and cost-effective. The company has expanded its footprint across Europe and Asia and has gained recognition as one of the most innovative startups globally, underscoring its commitment to modernizing transportation systems.

Hemovent

Series A in 2016
Hemovent is a medical technology company based in Aachen, Germany, focused on developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Founded by Christof Lenz and Oliver Marseille, the company aims to create an innovative device that supports or replaces heart and lung functions during cardiac or respiratory failure. Hemovent's device is designed to provide respiratory support for patients with severely damaged lungs and serves as a temporary life support system, taking over heart function in cases of acute heart failure. This technology enables hospitals to stabilize patients and address underlying health issues effectively, while also allowing for increased patient mobility during treatment.

NavVis

Series B in 2015
NavVis develops indoor spatial intelligence solutions, enabling enterprises to capture and share built environments as photorealistic digital twins. Its SLAM-based mobile mapping systems generate high-quality data with survey-grade accuracy, facilitating better operational decisions and improved productivity.

Efficient Energy

Venture Round in 2015
Efficient Energy GmbH, based in Feldkirchen near Munich, Germany, specializes in the development, manufacturing, and distribution of environmentally friendly refrigeration systems for both industrial and home applications. Established in 2006, the company is recognized for its innovative eChiller, which utilizes pure water as a refrigerant, effectively avoiding the use of harmful fluorinated gases. This technology addresses regulatory challenges in refrigeration while providing efficient cooling solutions for data centers, server rooms, and various industrial processes. The eChiller models offer cooling capacities ranging from 35 kW to 120 kW and are designed to deliver cost efficiency and a low carbon footprint. Efficient Energy also provides a range of services, including consulting, planning, installation, and maintenance, ensuring optimal energy efficiency for its clients. The company's pioneering work has garnered multiple awards, highlighting its commitment to sustainable practices in refrigeration technology.

Siltectra

Series B in 2015
SILTECTRA GmbH, founded in 2010 and based in Dresden, Germany, specializes in advanced laser-based wafering technology for semiconductor manufacturers. The company has developed innovative kerfless wafering and thinning solutions that enable the separation of wafers from semiconductor materials, such as silicon carbide, gallium nitride, and sapphire, without material loss. This technology is particularly beneficial for applications in solar inverters and various electronic devices, providing significant performance and cost advantages to the global semiconductor industry. SILTECTRA operates as a subsidiary of Infineon Technologies AG and aims to enhance manufacturing processes across multiple industries through its cutting-edge solutions.

Protagen

Venture Round in 2014
Protagen is a precision medicine company that specializes in drug development and patient management, particularly in the fields of autoimmune diseases and immuno-oncology. The company focuses on immuno-profiling and the discovery of novel autoantibody signatures, utilizing its SeroTag® technology to identify biomarkers that address challenges in the development of cancer immunotherapies and treatments for autoimmune conditions. Protagen is recognized for its expertise in patient stratification, having created disease-specific NavigAID panels that assess individual patients' autoimmune conditions and immune statuses. This tailored approach enables the development of more targeted therapies for various autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and Sjögren’s syndrome. Additionally, Protagen's biomarker discovery platform aids in the detection of autoantibodies in patients undergoing cancer immunotherapy, which helps predict treatment responses and supports informed therapeutic decisions.

NavVis

Series A in 2014
NavVis develops indoor spatial intelligence solutions, enabling enterprises to capture and share built environments as photorealistic digital twins. Its SLAM-based mobile mapping systems generate high-quality data with survey-grade accuracy, facilitating better operational decisions and improved productivity.

Siltectra

Series A in 2014
SILTECTRA GmbH, founded in 2010 and based in Dresden, Germany, specializes in advanced laser-based wafering technology for semiconductor manufacturers. The company has developed innovative kerfless wafering and thinning solutions that enable the separation of wafers from semiconductor materials, such as silicon carbide, gallium nitride, and sapphire, without material loss. This technology is particularly beneficial for applications in solar inverters and various electronic devices, providing significant performance and cost advantages to the global semiconductor industry. SILTECTRA operates as a subsidiary of Infineon Technologies AG and aims to enhance manufacturing processes across multiple industries through its cutting-edge solutions.

Isarna Therapeutics

Venture Round in 2014
Isarna Therapeutics is focused on the development of selective TGF-β inhibitors aimed at treating ophthalmic and fibrotic diseases, as well as combating cancer. The company is advancing an innovative pipeline that includes novel oligonucleotides and combination therapies, designed to enhance clinical responses and improve patient outcomes. By leveraging its expertise in the field, Isarna Therapeutics is committed to addressing unmet medical needs in ophthalmic care and beyond.

Isarna Therapeutics

Venture Round in 2014
Isarna Therapeutics is focused on the development of selective TGF-β inhibitors aimed at treating ophthalmic and fibrotic diseases, as well as combating cancer. The company is advancing an innovative pipeline that includes novel oligonucleotides and combination therapies, designed to enhance clinical responses and improve patient outcomes. By leveraging its expertise in the field, Isarna Therapeutics is committed to addressing unmet medical needs in ophthalmic care and beyond.

Ganymed Pharmaceuticals

Series E in 2013
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

SuppreMol

Series D in 2013
SuppreMol is a privately held biotechnology company that specializes in developing therapeutics for autoimmune and allergic diseases. The company is at the forefront of a novel approach aimed at treating these conditions by targeting their underlying causes rather than just alleviating symptoms. SuppreMol focuses on the development of soluble Fc-gamma receptors, which are recombinant autologous therapeutic proteins designed to exert specific immunoregulatory effects. This innovative strategy positions the company as a significant player in the field of immunotherapy, with the potential to advance treatment options for patients suffering from a range of autoimmune disorders.

Efficient Energy

Venture Round in 2013
Efficient Energy GmbH, based in Feldkirchen near Munich, Germany, specializes in the development, manufacturing, and distribution of environmentally friendly refrigeration systems for both industrial and home applications. Established in 2006, the company is recognized for its innovative eChiller, which utilizes pure water as a refrigerant, effectively avoiding the use of harmful fluorinated gases. This technology addresses regulatory challenges in refrigeration while providing efficient cooling solutions for data centers, server rooms, and various industrial processes. The eChiller models offer cooling capacities ranging from 35 kW to 120 kW and are designed to deliver cost efficiency and a low carbon footprint. Efficient Energy also provides a range of services, including consulting, planning, installation, and maintenance, ensuring optimal energy efficiency for its clients. The company's pioneering work has garnered multiple awards, highlighting its commitment to sustainable practices in refrigeration technology.

Siltectra

Series A in 2013
SILTECTRA GmbH, founded in 2010 and based in Dresden, Germany, specializes in advanced laser-based wafering technology for semiconductor manufacturers. The company has developed innovative kerfless wafering and thinning solutions that enable the separation of wafers from semiconductor materials, such as silicon carbide, gallium nitride, and sapphire, without material loss. This technology is particularly beneficial for applications in solar inverters and various electronic devices, providing significant performance and cost advantages to the global semiconductor industry. SILTECTRA operates as a subsidiary of Infineon Technologies AG and aims to enhance manufacturing processes across multiple industries through its cutting-edge solutions.

SuppreMol

Series D in 2012
SuppreMol is a privately held biotechnology company that specializes in developing therapeutics for autoimmune and allergic diseases. The company is at the forefront of a novel approach aimed at treating these conditions by targeting their underlying causes rather than just alleviating symptoms. SuppreMol focuses on the development of soluble Fc-gamma receptors, which are recombinant autologous therapeutic proteins designed to exert specific immunoregulatory effects. This innovative strategy positions the company as a significant player in the field of immunotherapy, with the potential to advance treatment options for patients suffering from a range of autoimmune disorders.

Siltectra

Seed Round in 2012
SILTECTRA GmbH, founded in 2010 and based in Dresden, Germany, specializes in advanced laser-based wafering technology for semiconductor manufacturers. The company has developed innovative kerfless wafering and thinning solutions that enable the separation of wafers from semiconductor materials, such as silicon carbide, gallium nitride, and sapphire, without material loss. This technology is particularly beneficial for applications in solar inverters and various electronic devices, providing significant performance and cost advantages to the global semiconductor industry. SILTECTRA operates as a subsidiary of Infineon Technologies AG and aims to enhance manufacturing processes across multiple industries through its cutting-edge solutions.

NFON

Venture Round in 2012
NFON is a Munich-based provider of cloud-based telecommunications services, specializing in integrated business communication solutions for corporate customers across Europe. The company's primary offering is its outsourced telephone system, known as IP Centrex, which delivers a comprehensive package designed to help businesses of all sizes reduce phone system costs by up to 50%. NFON's services encompass various aspects of business communication, including telephony, video calls, and screen sharing, along with necessary hardware components. The company also focuses on integration, ensuring that its cloud telephony system seamlessly fits into existing customer workflows and business processes. Additionally, NFON offers products aimed at optimizing customer contact, as well as services that prepare companies for cloud transition, enhancing their operational efficiency. With a fully redundant, high-performance computer center and over 100 functions, NFON is positioned as a key player in the telecommunications sector.

AFFiRiS

Venture Round in 2011
AFFiRiS AG is a biotechnology company based in Vienna, Austria, specializing in the development and manufacture of peptide-based vaccines aimed at the therapeutic treatment of chronic diseases with significant unmet medical needs. Founded in 2003, the company focuses on creating tailored vaccines for a range of conditions, including Alzheimer’s disease, Parkinson’s disease, atherosclerosis, hypertension, diabetes, psoriasis, allergies, asthma, and Huntington’s disease, among others. Through its innovative approach, AFFiRiS seeks to address critical health challenges and improve patient outcomes in various therapeutic areas.

IDENT Technology

Venture Round in 2011
IDENT Technology AG specializes in developing and licensing innovative technology solutions for near-field communication (NFC) and human-machine interface (HMI), focusing on capacitive near-field detection, interaction, and identification applications. Their flagship products include SKINPLEX GestIC for gesture detection, SKINPLEX zeropower sensor system for touchless sensing in harsh environments, and SKINPLEX ultra-low-power proximity system for device wake-up and power-down functionality. Established in 2002 and headquartered in Wessling, Germany, IDENT Technology serves a diverse range of industries such as consumer electronics, automotive, healthcare, and telecommunications.

Isarna Therapeutics

Venture Round in 2011
Isarna Therapeutics is focused on the development of selective TGF-β inhibitors aimed at treating ophthalmic and fibrotic diseases, as well as combating cancer. The company is advancing an innovative pipeline that includes novel oligonucleotides and combination therapies, designed to enhance clinical responses and improve patient outcomes. By leveraging its expertise in the field, Isarna Therapeutics is committed to addressing unmet medical needs in ophthalmic care and beyond.

CYNORA

Series A in 2011
CYNORA GmbH is a Bruchsal, Germany-based company specializing in the development and manufacturing of organic electronics, particularly for organic light-emitting diode (OLED) displays. Founded in 2008, CYNORA focuses on creating advanced materials that utilize Thermally Activated Delayed Fluorescence (TADF) technology to produce efficient blue and green emitters. These emitters are designed to enhance the power efficiency and color contrast of OLED devices, addressing the growing demand for thinner, flexible screens with improved performance and lower energy consumption. By providing iridium-free, purely organic emitter systems tailored for modern vacuum processing, CYNORA aims to deliver significant value to OLED producers and meet the evolving expectations within the display market.

AMSilk

Series B in 2011
AMSilk GmbH is a Munich-based company that specializes in the production of spider silk proteins and other biomaterials for a variety of industrial applications. Founded in 2008, AMSilk manufactures high-quality silk biopolymers that serve diverse sectors, including pharmaceuticals, cosmetics, and technical textiles. Its product offerings include BioShield-S1, a non-immunogenic spider silk film for protective coatings, as well as biosteel spider silk fibers. The company also develops a range of wound care products and surgical applications, such as the SanaSilk durable skin barrier. Additionally, AMSilk provides spider silk protein beads and coatings for medical technology, alongside nonwovens for filters, wound dressings, and specialty textiles. Utilizing a patented biotechnological process, AMSilk's materials are fully biodegradable under aerobic and marine conditions, promoting sustainability in various applications. The company collaborates with partners like Gruschwitz Textilwerke AG to enhance its product offerings.

Efficient Energy

Venture Round in 2011
Efficient Energy GmbH, based in Feldkirchen near Munich, Germany, specializes in the development, manufacturing, and distribution of environmentally friendly refrigeration systems for both industrial and home applications. Established in 2006, the company is recognized for its innovative eChiller, which utilizes pure water as a refrigerant, effectively avoiding the use of harmful fluorinated gases. This technology addresses regulatory challenges in refrigeration while providing efficient cooling solutions for data centers, server rooms, and various industrial processes. The eChiller models offer cooling capacities ranging from 35 kW to 120 kW and are designed to deliver cost efficiency and a low carbon footprint. Efficient Energy also provides a range of services, including consulting, planning, installation, and maintenance, ensuring optimal energy efficiency for its clients. The company's pioneering work has garnered multiple awards, highlighting its commitment to sustainable practices in refrigeration technology.

SuppreMol

Series C in 2010
SuppreMol is a privately held biotechnology company that specializes in developing therapeutics for autoimmune and allergic diseases. The company is at the forefront of a novel approach aimed at treating these conditions by targeting their underlying causes rather than just alleviating symptoms. SuppreMol focuses on the development of soluble Fc-gamma receptors, which are recombinant autologous therapeutic proteins designed to exert specific immunoregulatory effects. This innovative strategy positions the company as a significant player in the field of immunotherapy, with the potential to advance treatment options for patients suffering from a range of autoimmune disorders.

Corimmun

Series B in 2010
Corimmun is a clinical drug development company based in Martinsried, near Munich, Germany, specializing in innovative therapeutics and diagnostics for heart and vascular diseases. The company is dedicated to addressing unmet medical needs in the field of cardiovascular health. Corimmun's expertise encompasses the entire process of drug development, from initial research through to commercialization. By focusing on novel treatment options, Corimmun aims to improve outcomes for patients suffering from cardiovascular conditions.

immatics biotechnologies

Series C in 2010
immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

IDENT Technology

Venture Round in 2010
IDENT Technology AG specializes in developing and licensing innovative technology solutions for near-field communication (NFC) and human-machine interface (HMI), focusing on capacitive near-field detection, interaction, and identification applications. Their flagship products include SKINPLEX GestIC for gesture detection, SKINPLEX zeropower sensor system for touchless sensing in harsh environments, and SKINPLEX ultra-low-power proximity system for device wake-up and power-down functionality. Established in 2002 and headquartered in Wessling, Germany, IDENT Technology serves a diverse range of industries such as consumer electronics, automotive, healthcare, and telecommunications.

Biocrates Life Sciences

Venture Round in 2010
Biocrates Life Sciences AG is a biotechnology company based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions. Founded in 2002, the company develops and markets mass-spectrometry based kits and services that facilitate the analysis of endogenous metabolites. These tools are essential for discovering and validating biomarkers associated with complex multifactorial diseases, including cancer and neurodegenerative disorders. Biocrates provides a comprehensive metabolomics platform that integrates automated sample preparation workflows with advanced mass-spectrometric techniques, enabling rapid and reliable identification of hundreds of metabolites. Their products and services cater to a wide range of research areas, such as cardiovascular health, diabetes, endocrinology, pharmacology, and more. Biocrates Life Sciences distributes its solutions through authorized partners across various regions, including the Middle East, Europe, and parts of Asia.

Isarna Therapeutics

Venture Round in 2010
Isarna Therapeutics is focused on the development of selective TGF-β inhibitors aimed at treating ophthalmic and fibrotic diseases, as well as combating cancer. The company is advancing an innovative pipeline that includes novel oligonucleotides and combination therapies, designed to enhance clinical responses and improve patient outcomes. By leveraging its expertise in the field, Isarna Therapeutics is committed to addressing unmet medical needs in ophthalmic care and beyond.

PDC Biotech

Series A in 2010
PDC Biotech GmbH is a biotechnology company based in Vienna, Austria, specializing in the development of innovative therapeutics for the treatment of preterm labor and primary dysmenorrhea, addressing significant unmet medical needs. Founded in 2008, the company focuses on a pipeline of products that target the prostaglandin F2α (FP) receptor, including synthetic octapeptides designed as allosteric modulators of this receptor. Key products in development include PDC31 and the PDC41 Series, a non-intravenous formulation intended for self-administration by patients. PDC Biotech employs various delivery methods for its formulations, such as nasal, sublingual, pulmonary, vaginal, and rectal suppositories. The company has secured exclusive worldwide rights to a family of FP receptor antagonists, enabling it to advance its therapeutic offerings in the biopharmaceutical sector.

Protagen

Venture Round in 2009
Protagen is a precision medicine company that specializes in drug development and patient management, particularly in the fields of autoimmune diseases and immuno-oncology. The company focuses on immuno-profiling and the discovery of novel autoantibody signatures, utilizing its SeroTag® technology to identify biomarkers that address challenges in the development of cancer immunotherapies and treatments for autoimmune conditions. Protagen is recognized for its expertise in patient stratification, having created disease-specific NavigAID panels that assess individual patients' autoimmune conditions and immune statuses. This tailored approach enables the development of more targeted therapies for various autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and Sjögren’s syndrome. Additionally, Protagen's biomarker discovery platform aids in the detection of autoantibodies in patients undergoing cancer immunotherapy, which helps predict treatment responses and supports informed therapeutic decisions.

Sovicell

Venture Round in 2009
Sovicell specializes in the development and provision of advanced bio-analytical products and services that focus on ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicology) testing. The company offers a range of kits designed to facilitate drug discovery by delivering rapid and reliable pharmacokinetic data and side-effect predictions for drug candidates and other test substances. By enabling customers to obtain accurate and reproducible results, Sovicell supports the critical processes involved in evaluating the safety and efficacy of new pharmaceuticals.

Ganymed Pharmaceuticals

Series D in 2008
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

Efficient Energy

Seed Round in 2008
Efficient Energy GmbH, based in Feldkirchen near Munich, Germany, specializes in the development, manufacturing, and distribution of environmentally friendly refrigeration systems for both industrial and home applications. Established in 2006, the company is recognized for its innovative eChiller, which utilizes pure water as a refrigerant, effectively avoiding the use of harmful fluorinated gases. This technology addresses regulatory challenges in refrigeration while providing efficient cooling solutions for data centers, server rooms, and various industrial processes. The eChiller models offer cooling capacities ranging from 35 kW to 120 kW and are designed to deliver cost efficiency and a low carbon footprint. Efficient Energy also provides a range of services, including consulting, planning, installation, and maintenance, ensuring optimal energy efficiency for its clients. The company's pioneering work has garnered multiple awards, highlighting its commitment to sustainable practices in refrigeration technology.

Corimmun

Series A in 2008
Corimmun is a clinical drug development company based in Martinsried, near Munich, Germany, specializing in innovative therapeutics and diagnostics for heart and vascular diseases. The company is dedicated to addressing unmet medical needs in the field of cardiovascular health. Corimmun's expertise encompasses the entire process of drug development, from initial research through to commercialization. By focusing on novel treatment options, Corimmun aims to improve outcomes for patients suffering from cardiovascular conditions.

Protagen

Venture Round in 2008
Protagen is a precision medicine company that specializes in drug development and patient management, particularly in the fields of autoimmune diseases and immuno-oncology. The company focuses on immuno-profiling and the discovery of novel autoantibody signatures, utilizing its SeroTag® technology to identify biomarkers that address challenges in the development of cancer immunotherapies and treatments for autoimmune conditions. Protagen is recognized for its expertise in patient stratification, having created disease-specific NavigAID panels that assess individual patients' autoimmune conditions and immune statuses. This tailored approach enables the development of more targeted therapies for various autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and Sjögren’s syndrome. Additionally, Protagen's biomarker discovery platform aids in the detection of autoantibodies in patients undergoing cancer immunotherapy, which helps predict treatment responses and supports informed therapeutic decisions.

SuppreMol

Series B in 2008
SuppreMol is a privately held biotechnology company that specializes in developing therapeutics for autoimmune and allergic diseases. The company is at the forefront of a novel approach aimed at treating these conditions by targeting their underlying causes rather than just alleviating symptoms. SuppreMol focuses on the development of soluble Fc-gamma receptors, which are recombinant autologous therapeutic proteins designed to exert specific immunoregulatory effects. This innovative strategy positions the company as a significant player in the field of immunotherapy, with the potential to advance treatment options for patients suffering from a range of autoimmune disorders.

Protagen

Venture Round in 2008
Protagen is a precision medicine company that specializes in drug development and patient management, particularly in the fields of autoimmune diseases and immuno-oncology. The company focuses on immuno-profiling and the discovery of novel autoantibody signatures, utilizing its SeroTag® technology to identify biomarkers that address challenges in the development of cancer immunotherapies and treatments for autoimmune conditions. Protagen is recognized for its expertise in patient stratification, having created disease-specific NavigAID panels that assess individual patients' autoimmune conditions and immune statuses. This tailored approach enables the development of more targeted therapies for various autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and Sjögren’s syndrome. Additionally, Protagen's biomarker discovery platform aids in the detection of autoantibodies in patients undergoing cancer immunotherapy, which helps predict treatment responses and supports informed therapeutic decisions.

Isarna Therapeutics

Venture Round in 2007
Isarna Therapeutics is focused on the development of selective TGF-β inhibitors aimed at treating ophthalmic and fibrotic diseases, as well as combating cancer. The company is advancing an innovative pipeline that includes novel oligonucleotides and combination therapies, designed to enhance clinical responses and improve patient outcomes. By leveraging its expertise in the field, Isarna Therapeutics is committed to addressing unmet medical needs in ophthalmic care and beyond.

Sovicell

Series D in 2007
Sovicell specializes in the development and provision of advanced bio-analytical products and services that focus on ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicology) testing. The company offers a range of kits designed to facilitate drug discovery by delivering rapid and reliable pharmacokinetic data and side-effect predictions for drug candidates and other test substances. By enabling customers to obtain accurate and reproducible results, Sovicell supports the critical processes involved in evaluating the safety and efficacy of new pharmaceuticals.

Biocrates Life Sciences

Series A in 2006
Biocrates Life Sciences AG is a biotechnology company based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions. Founded in 2002, the company develops and markets mass-spectrometry based kits and services that facilitate the analysis of endogenous metabolites. These tools are essential for discovering and validating biomarkers associated with complex multifactorial diseases, including cancer and neurodegenerative disorders. Biocrates provides a comprehensive metabolomics platform that integrates automated sample preparation workflows with advanced mass-spectrometric techniques, enabling rapid and reliable identification of hundreds of metabolites. Their products and services cater to a wide range of research areas, such as cardiovascular health, diabetes, endocrinology, pharmacology, and more. Biocrates Life Sciences distributes its solutions through authorized partners across various regions, including the Middle East, Europe, and parts of Asia.

Protagen

Series B in 2006
Protagen is a precision medicine company that specializes in drug development and patient management, particularly in the fields of autoimmune diseases and immuno-oncology. The company focuses on immuno-profiling and the discovery of novel autoantibody signatures, utilizing its SeroTag® technology to identify biomarkers that address challenges in the development of cancer immunotherapies and treatments for autoimmune conditions. Protagen is recognized for its expertise in patient stratification, having created disease-specific NavigAID panels that assess individual patients' autoimmune conditions and immune statuses. This tailored approach enables the development of more targeted therapies for various autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and Sjögren’s syndrome. Additionally, Protagen's biomarker discovery platform aids in the detection of autoantibodies in patients undergoing cancer immunotherapy, which helps predict treatment responses and supports informed therapeutic decisions.

Isarna Therapeutics

Private Equity Round in 2005
Isarna Therapeutics is focused on the development of selective TGF-β inhibitors aimed at treating ophthalmic and fibrotic diseases, as well as combating cancer. The company is advancing an innovative pipeline that includes novel oligonucleotides and combination therapies, designed to enhance clinical responses and improve patient outcomes. By leveraging its expertise in the field, Isarna Therapeutics is committed to addressing unmet medical needs in ophthalmic care and beyond.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.